The global glaucoma treatment market size accounted for USD 6.72 billion in 2025 and is forecasted to hit around USD 8.66 billion by 2034, representing a CAGR of 2.86% from 2025 to 2034. The North America market size was estimated at USD 2.33 billion in 2024 and is expanding at a CAGR of 2.92% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Glaucoma Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Glaucoma Treatment Market, by Disease Type
8.1.1. Open Angle Glaucoma
8.1.1.1. Market Revenue and Forecast
8.1.2. Angle Closure Glaucoma
8.1.2.1. Market Revenue and Forecast
8.1.3. Others
8.1.3.1. Market Revenue and Forecast
9.1. Glaucoma Treatment Market, by Drug Class
9.1.1. Prostaglandin Analogs
9.1.1.1. Market Revenue and Forecast
9.1.2. Beta Blockers
9.1.2.1. Market Revenue and Forecast
9.1.3. Alpha Agonist
9.1.3.1. Market Revenue and Forecast
9.1.4. Carbonic Anhydrase Inhibitors
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast
10.1. Glaucoma Treatment Market, by Distribution Channel
10.1.1. Hospital Pharmacy
10.1.1.1. Market Revenue and Forecast
10.1.2. Retail Pharmacy
10.1.2.1. Market Revenue and Forecast
10.1.3. Online Pharmacy
10.1.3.1. Market Revenue and Forecast
11.1. Glaucoma Treatment Market, by Formulation
11.1.1. Solid
11.1.1.1. Market Revenue and Forecast
11.1.2. Liquid
11.1.2.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Disease Type
12.1.2. Market Revenue and Forecast, by Drug Class
12.1.3. Market Revenue and Forecast, by Distribution Channel
12.1.4. Market Revenue and Forecast, by Formulation
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Disease Type
12.1.5.2. Market Revenue and Forecast, by Drug Class
12.1.5.3. Market Revenue and Forecast, by Distribution Channel
12.1.5.4. Market Revenue and Forecast, by Formulation
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Disease Type
12.1.6.2. Market Revenue and Forecast, by Drug Class
12.1.6.3. Market Revenue and Forecast, by Distribution Channel
12.1.6.4. Market Revenue and Forecast, by Formulation
12.2. Europe
12.2.1. Market Revenue and Forecast, by Disease Type
12.2.2. Market Revenue and Forecast, by Drug Class
12.2.3. Market Revenue and Forecast, by Distribution Channel
12.2.4. Market Revenue and Forecast, by Formulation
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Disease Type
12.2.5.2. Market Revenue and Forecast, by Drug Class
12.2.5.3. Market Revenue and Forecast, by Distribution Channel
12.2.5.4. Market Revenue and Forecast, by Formulation
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Disease Type
12.2.6.2. Market Revenue and Forecast, by Drug Class
12.2.6.3. Market Revenue and Forecast, by Distribution Channel
12.2.6.4. Market Revenue and Forecast, by Formulation
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Disease Type
12.2.7.2. Market Revenue and Forecast, by Drug Class
12.2.7.3. Market Revenue and Forecast, by Distribution Channel
12.2.7.4. Market Revenue and Forecast, by Formulation
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Disease Type
12.2.8.2. Market Revenue and Forecast, by Drug Class
12.2.8.3. Market Revenue and Forecast, by Distribution Channel
12.2.8.4. Market Revenue and Forecast, by Formulation
12.3. APAC
12.3.1. Market Revenue and Forecast, by Disease Type
12.3.2. Market Revenue and Forecast, by Drug Class
12.3.3. Market Revenue and Forecast, by Distribution Channel
12.3.4. Market Revenue and Forecast, by Formulation
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Disease Type
12.3.5.2. Market Revenue and Forecast, by Drug Class
12.3.5.3. Market Revenue and Forecast, by Distribution Channel
12.3.5.4. Market Revenue and Forecast, by Formulation
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Disease Type
12.3.6.2. Market Revenue and Forecast, by Drug Class
12.3.6.3. Market Revenue and Forecast, by Distribution Channel
12.3.6.4. Market Revenue and Forecast, by Formulation
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Disease Type
12.3.7.2. Market Revenue and Forecast, by Drug Class
12.3.7.3. Market Revenue and Forecast, by Distribution Channel
12.3.7.4. Market Revenue and Forecast, by Formulation
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Disease Type
12.3.8.2. Market Revenue and Forecast, by Drug Class
12.3.8.3. Market Revenue and Forecast, by Distribution Channel
12.3.8.4. Market Revenue and Forecast, by Formulation
12.4. MEA
12.4.1. Market Revenue and Forecast, by Disease Type
12.4.2. Market Revenue and Forecast, by Drug Class
12.4.3. Market Revenue and Forecast, by Distribution Channel
12.4.4. Market Revenue and Forecast, by Formulation
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Disease Type
12.4.5.2. Market Revenue and Forecast, by Drug Class
12.4.5.3. Market Revenue and Forecast, by Distribution Channel
12.4.5.4. Market Revenue and Forecast, by Formulation
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Disease Type
12.4.6.2. Market Revenue and Forecast, by Drug Class
12.4.6.3. Market Revenue and Forecast, by Distribution Channel
12.4.6.4. Market Revenue and Forecast, by Formulation
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Disease Type
12.4.7.2. Market Revenue and Forecast, by Drug Class
12.4.7.3. Market Revenue and Forecast, by Distribution Channel
12.4.7.4. Market Revenue and Forecast, by Formulation
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Disease Type
12.4.8.2. Market Revenue and Forecast, by Drug Class
12.4.8.3. Market Revenue and Forecast, by Distribution Channel
12.4.8.4. Market Revenue and Forecast, by Formulation
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Disease Type
12.5.2. Market Revenue and Forecast, by Drug Class
12.5.3. Market Revenue and Forecast, by Distribution Channel
12.5.4. Market Revenue and Forecast, by Formulation
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Disease Type
12.5.5.2. Market Revenue and Forecast, by Drug Class
12.5.5.3. Market Revenue and Forecast, by Distribution Channel
12.5.5.4. Market Revenue and Forecast, by Formulation
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Disease Type
12.5.6.2. Market Revenue and Forecast, by Drug Class
12.5.6.3. Market Revenue and Forecast, by Distribution Channel
12.5.6.4. Market Revenue and Forecast, by Formulation
13.1. AERIE Pharmaceuticals, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Cipla Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Akorn Operating Company LLC
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. AbbVie
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Bausch & Lomb Incorporated
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Inoteck Pharmaceuticals
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Merck & Co., Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Pfizer Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Santen Pharmaceutical Co., Ltd.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample